Last 1,449 GBp
Change Today +12.50 / 0.87%
Volume 19.2M
GSK On Other Exchanges
New York
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GSK) Snapshot

1,450 GBp
Previous Close
1,437 GBp
Day High
1,456 GBp
Day Low
1,433 GBp
52 Week High
02/21/14 - 1,706 GBp
52 Week Low
08/8/14 - 1,365 GBp
Market Cap
Average Volume 10 Days
0.99 GBp
Shares Outstanding
88.89 GBp
Dividend Yield
Current Stock Chart for GLAXOSMITHKLINE PLC (GSK)

glaxosmithkline plc (GSK) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc (GSK) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc (GSK) Key Developments

China Court Fines GlaxoSmithKline $492 Million for Bribery

GlaxoSmithKline was fined $492 million for bribing doctors in China. The court sentenced the company's former China manager, Briton Mark Reilly, and four Chinese co-defendants to prison but postponed the sentences for two to four years, suggesting they may never be served. The court said it granted leniency because the defendants confessed. The case, first publicized in mid-2013, highlighted the widespread use of payments to doctors and hospitals by sellers of drugs and medical equipment in a poorly funded health system that Chinese leaders have promised to improve. Glaxo said it would pay the fine and had made changes in its business to remedy flaws cited by Chinese authorities. It said it would change the incentive system for employees and reduce its engagement with health professionals.

GSK Announces First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study

GSK announced that the first phase IIIb/IV study, conducted in collaboration with Gilead Sciences Inc., to investigate combination therapy of ambrisentan and tadalafil in treatment naïve patients with pulmonary arterial hypertension met the primary endpoint (time to first clinical failure event) by showing superiority of the combination therapy compared to mono therapy treatment (ambrisentan or tadalafil). The length of time before patients experienced clinical failure was significantly prolonged for those receiving first-line combination compared to mono therapy. Study showed that first-line treatment of PAH with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50% compared to pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint. Statistically significant improvements were also observed for three of the secondary endpoints (6 minute walk distance test, percentage of patients with satisfactory clinical response, change from baseline in N-terminal pro-B-type natriuretic peptide). The remaining two secondary endpoints (WHO functional class and Borg dyspnea index) did not meet statistical significance. Rates of serious adverse events and events to discontinuation were similar across treatment arms. Detailed results from the study (Abstract #2916) were presented during an oral session at the annual meeting of the European Respiratory Society (ERS). The data provided by the AMBITION study represent one of the most important steps forward in the treatment of patients with PAH. The 50% risk reduction for clinical failure achieved with upfront combination therapy as compared to upfront mono therapy, indicates that this combination treatment strategy could potentially become the standard of care in treatment naïve PAH patients with WHO/NYHA functional class II and III symptoms.

Austrian biotech opening Phila.-area office

Philadelphia Inquirer September 7, 2014 CITY-D Edition Austrian biotech opening Phila.-area office BYLINE:Â By David Sell; Inquirer Staff Writer SECTION:Â BUSINESS; P-com Biz; Pg.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:LN 1,449.00 GBp +12.50

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $146.69 USD -0.15
Amgen Inc $144.01 USD +1.99
AstraZeneca PLC 4,579 GBp +42.00
Bayer AG €112.33 EUR +0.32
Novo Nordisk A/S kr281.70 DKK +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation GSK Industry Range
Price/Earnings 14.2x
Price/Sales 2.7x
Price/Book 10.8x
Price/Cash Flow 14.1x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at